中概股美国上市称被骗1000万美元,对方为承销商介绍的投资机构
来自江苏扬州广陵区头桥镇的美华国际(MHUA),于8月21日披露其2022年报,在其年报的第8页披露其风险:
https://www.sec.gov/Archives/edgar/data/1835615/000121390023069495/f20f2022a2_meihua.htm
与我们的业务和行业相关的风险
美华国际(MHUA)在2022年2月IPO时,公司与一家香港实体签订了某些协议,据此公司认为被骗逾1000万美元;由于公司未能在首次公开募股时披露此类协议,无论此类协议是否具有欺诈性质,公司都可能因此类协议而承担潜在的责任或诉讼风险。
公司于2022年2月18日结束了IPO,通过以每股10美元的发行价发行394万股普通股募资3,940万美元。在IPO路演期间,公司联席承销商Shengang Securities Company Limited(Shengang)向公司介绍了一家名为Tai He International Group Limited(Tai He)的香港投资公司。Tai He经与Shengang协商,表示将作为投资者参与此次IPO。
作为一家处于发展阶段的中国医疗器械公司,公司管理层没有美国资本市场经验,依赖投资银行家和承销商为其美国公开发行提供指导和建议。因此,公司并不清楚Tai He的实际动机。基于公司对Shengang的信任,并考虑到公司无法进一步核实的情况,公司仓促与Tai He签订了一系列协议(Tai He Agreements)。
根据协议,Tai He同意在首次公开募股中投资至少3500万美元,但公司需缴纳700万美元的可退还押金(可退还押金)并预付300万美元的投资者关系和其他服务服务费(服务)应付给Tai He。公司、其关联公司及个人股东于2022年1月27日至2022年3月11日期间分期向Tai He支付了700万美元可退还押金和300万美元服务费。2022年3月11日后,公司未向Tai He支付其他款项 ,亦与Tai He没有任何直接互动,事实上,公司在谈判期间从未与Tai He直接沟通,仅通过Shengang进行沟通。
IPO后,通过公司内部风险控制流程,公司了解到Tai He似乎并非公司投资者,当公司试图询问时,Tai He拒绝与公司交谈。根据公司调查及了解的事实,公司认为其被Tai He诈骗,且Tai He从未实际投资3,500万美元进行IPO。事实上,公司获悉Tai He根本没有对公司进行任何投资,Tai He也没有参与公司的IPO事宜。此外,Tai He尚未向公司偿还可退还按金,且未向公司提供任何服务。因此,公司认为,Tai He Agreements可能被视为Tai He及Shengang利用不对称信息,包括公司对美国市场、IPO规则缺乏认识和了解等,对公司实施的欺诈行为。
经咨询专业人士后,公司现知悉Tai He Agreements须向公众披露,且公司认为协议本身具有欺诈性且不可执行,因此公司现将Tai He Agreements披露以满足美国证券交易委员会(SEC)的合规要求。此外,公司承认,其在订立Tai He Agreements时不当依赖Shengang的意见、指示及顾问。公司现正积极努力终止Tai He Agreements并收回公司已支付给Tai He的款项。由于收款的不确定性,公司已核销约480万美元的押金,并全额支出公司截至2022年12月31日止年度向Tai He支付的230万美元的服务费。公司及其执行管理团队拟与Tai He合作SEC以及任何其他相关机构,以确保在解决此类问题时保护投资者的利益。尽管如此,Tai He Agreements的存在以及公司未能披露这些协议可能会使公司面临潜在的股东诉讼和/或SEC执法或其他监管行动。
In connection with the initial public offering of our Ordinary Shares in February 2022, we entered into certain agreements with a Hong Kong entity pursuant to which we believe we were defrauded of in excess of $10 million; because we failed to disclose such agreements at the time of the initial public offering, regardless of the arguably fraudulent nature of such agreements, we may be subject to potential liabilities or litigation exposure as a result of such agreements.
The Company closed its initial public offering (the “IPO”) of its ordinary shares (the “Ordinary Shares”) on February 18, 2022, through which the Company raised $39.4 million through the sale of 3,940,000 Ordinary Shares at a purchase price of $10.00 per share. During the roadshow leading up to the IPO, a Hong Kong investment company named Tai He International Group Limited (“Tai He”) was referred to the Company by Shengang Securities Company Limited (“Shengang”), the Company’s co-underwriter based in the People’s Republic of China (“PRC”). Tai He, through negotiations with Shengang, asserted that it would participate in the IPO as an investor. As a development stage PRC medical device company, the Company’s management had no experience in the U.S. capital markets and relied on its investment bankers and underwriters in providing guidance and advice concerning its U.S. public offering. Accordingly, the Company was unaware of the actual motives of Tai He. Based on the Company’s trust in Shengang and given the circumstances that the Company was unable to make further verification, the Company hastily entered into a series of agreements with Tai He (the “Tai He Agreements”).
Pursuant to the Tai He Agreements, Tai He agreed to invest a minimum of $35 million in the IPO subject to the Company making a $7.0 million refundable deposit (the “Refundable Deposit”) and advancing a $3.0 million service fee for investor relations and other services (together, the “Services”) payable to Tai He. The Company, its affiliates and individual shareholders paid the $7.0 million Refundable Deposit and $3.0 million service fee to Tai He in several installments from January 27, 2022 to March 11, 2022. After March 11, 2022, the Company has made no other payments to, nor had any direct interaction with, Tai He, and, in actuality, the Company never directly communicated with Tai He during the negotiations, only communicating about Tai He and the Tai He Agreements through Shengang.
After the IPO, through the Company’s internal risk control process, the Company learned that Tai He does not appear to be an investor in the Company and, when the Company attempted to inquire about it, Tai He refused to speak with the Company. Based on the facts as investigated and understood by the Company, the Company believes that it was defrauded by Tai He and that Tai He never actually invested $35 million in the IPO. In fact, the Company learned that Tai He made no investments in the Company at all, and Tai He has no involvement in the Company’s IPO matters. In addition, the Refundable Deposit has not been repaid to the Company and no Services have been provided to the Company by Tai He. As a result, the Company believes that the Tai He Agreements may be deemed a fraud perpetrated by Tai He and Shengang against the Company by Tai He taking advantage of asymmetric information, including the Company’s lack of knowledge and understanding of the U.S. markets, IPO rules and processes, and the trust of the Company.
After consultation with professionals, the Company is now aware that the Tai He Agreements were required to be disclosed to the public and the Company believes that the agreements themselves are fraudulent and non-enforceable, and therefore the Company is disclosing the Tai He Agreements to meet the compliance requirements of the Securities and Exchange Commission (“SEC”). Further, the Company acknowledges that it had improperly relied on the advice, direction and counsel of Shengang when entering into the Tai He Agreements. The Company is now proactively working to terminate the Tai He Agreements and recover the monies already paid to Tai He by the Company. Due to the uncertainty of collection, the Company has written off approximately $4.8 million deposit and fully expensed $2.3 million service fee paid by the Company to Tai He in the year ended December 31, 2022. The Company and its executive management team intends to cooperate with the SEC, as well as any other relevant authorities, to ensure that its investors’ interests are protected while such matters are resolved. Nonetheless, the existence of the Tai He Agreements and the Company’s failure to disclose them could expose the Company potential shareholder litigation and/or SEC enforcement or other regulatory action.
版权申明
文章部分为转载,并不用于任何商业目的,我们已经尽可能的对作者和来源进行了通告,但是能力有限或疏忽,造成漏登,请及时联系我们,我们将根据著作权人的要求,立即更正或者删除有关内容。
声明:该文章系转载,登载该文章目的为更广泛的传递市场信息,不代表跟公司赞同其观点。文章内容仅供参考。
★我们是谁?华尔街纳斯达克上市有限公司
公司总部位于美国纽约曼哈顿,跨国精品投行,业务涵盖纽约、洛杉矶、香港、台湾、北京、上海、深圳、重庆、新加坡,伦敦等地区,既有传统投行业务又有新兴创新业务。
1)为企业海外上市设计顶层方案;全程辅导和保荐;首发公开募集(IPO)及上市后再融资;
2)担当SPAC发起人,负责设立专项造壳基金和IPO的股票承销,以及后续标的寻找和De-SPAC 合并全程统筹;代表标的公司,寻找、匹配已经完成上市的SPAC壳,设计交易方案,帮助标的公司搭建海外架构和系列文件,直至完成合并;
3)OTC造壳、买壳、更名、反向并购装资产,以及后续NASDAQ和NYSE转板上市;
4)上市公司并购重组;定向增发;市值管理;
5)PIPE(上市前、后私募股权投资);
6)财务咨询及估值模型建立服务;
7)上市前后股权激励方案设计、落地和兑现安排;
8)商业计划书策划和撰写;公平性意见函发布;
9)禁售股解禁销售;非交易性路演;投资者关系和危机处理等。
联系我们
微信扫码关注该文公众号作者